<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15/A
Certification and Notice of Termination of Registration under Section 12(g) of
the Securities Exchange Act of 1934 or Suspension of Duty to File Reports under
Sections 13 and 15(d) of the Securities Exchange Act of 1934.
Commission File Number: 0-19918
NEOZYME II CORPORATION
(Exact name of registrant as specified in its charter)
TODMAN BUILDING, MAIN STREET
ROAD TOWN, TORTOLA, BRITISH VIRGIN ISLANDS
(809) 494-2065
(Address, including zip code, and telephone number, including area code,
of registrant's principal executive offices)
UNITS*, EACH CONSISTING OF ONE SHARE OF CALLABLE COMMON STOCK, $1.00 PAR
VALUE, OF NEOZYME II CORPORATION AND ONE CALLABLE WARRANT TO PURCHASE TWO SHARES
OF GENERAL DIVISION COMMON STOCK, $0.01 PAR VALUE, AND .135 SHARE OF TISSUE
REPAIR DIVISION COMMON STOCK, $0.01 PAR VALUE, OF GENZYME CORPORATION
(Title of each class of securities covered by this Form)
NONE
(Titles of all other classes of securities for which a duty to file reports
under Section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)(i) [X] Rule 12h-3(b)(1)(ii) [ ]
Rule 12g-4(a)(1)(ii) [ ] Rule 12h-3(b)(2)(i) [ ]
Rule 12g-4(a)(2)(i) [ ] Rule 12h-3(b)(2)(i) [ ]
Rule 12g-4(a)(2)(ii) [ ] Rule 12h-3(b)(2)(ii) [ ]
Rule 12h-3(b)(1)(i) [X] Rule 15d-6 [ ]
Approximate number of holders of record as of the certification or notice
date: 0
- -----------------------
* On November 8, 1996, Neozyme II Corporation ("Neozyme II") filed a Form 15
with respect to shares of its Callable Common Stock included in the Units
deregistered hereby. As of such date, there were 22 record holders of the Units.
This amendment is being filed to include the Units, which were registered under
Section 12(g) by Neozyme II on July 10, 1992.
<PAGE> 2
Pursuant to the requirements of the Securities Exchange Act of 1934 GENZYME
CORPORATION has caused this certification/notice to be signed on behalf of
NEOZYME II CORPORATION, as its successor by merger, by the undersigned duly
authorized person.
Date: January 17, 1997 GENZYME CORPORATION
By: /s/ Peter Wirth
-----------------------------------
Peter Wirth
Executive Vice President
and Chief Legal Counsel
